Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant
A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant
Sponsor: Acorda Therapeutics
Terminated
New Safety Information
Other terminated trials from Acorda Therapeutics
Other Hepatic Impairment trials with similar outcome
This PHASE1 trial investigates Hepatic Impairment and is currently terminated or withdrawn. Acorda Therapeutics leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
▶ Show 2 earlier versions
-
Dec 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2017 — Dec 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Acorda Therapeutics
- Biotie Therapies Inc.
For direct contact, visit the study record on ClinicalTrials.gov .